title: Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo.
abstract: Neamine, a non-toxic derivative of neomycin, has recently been shown to have antitumor activities in various types of cancers. However, its effect on pancreatic cancer is still unknown. The study aimed to investigate its antitumor activity on pancreatic cancer and the underlying mechanisms. MTT assay was used to observe the effect of neamine on angiogenin (ANG)-induced AsPC-1 cell proliferation. Tissue microassay and immunofluorescence staining were used to detect the expression of ANG and its nuclear translocation, respectively. Tumor xenografts were established by subcutaneous inoculation of AsPC-1 pancreatic cancer cells into the right flanks of nude mice, and neamine was injected subcutaneously. Immunohistochemistry was done to observe the expression of ANG, CD31 and Ki-67 in tumor xenografts. It was found that neamine blocked the nuclear translocation of ANG effectively and inhibited ANG-induced AsPC-1 cell proliferation in a dose-dependent manner. Neamine had anti-tumor effects on AsPC-1 xenograft models. Consistently, neamine reduced the expression levels of ANG, Ki-67 and CD31 in tumor xenografts. It was concluded that neamine may be a promising agent for treatment of pancreatic cancer.
authors.affiliation: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Ya-Ping
authors.initials: YP
authors.lastname: Liu
authors.affiliation: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Wu
authors.affiliation: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Zhang
authors.affiliation: Molecular Oncology Research Institute, Tufts Medical Center, Boston, 02111, USA.
authors.forename: Guo-Fu
authors.initials: GF
authors.lastname: Hu
authors.affiliation: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. wuyunxia@hust.edu.cn.
authors.forename: Yun-Xia
authors.initials: YX
authors.lastname: Wu
mesh_terms: D000328:Adult; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D005601:Framycetin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000235:genetics / Q000378:metabolism; D012259:Ribonuclease, Pancreatic / Q000235:genetics / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D019394:Ki-67 Antigen; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D005601:Framycetin; C488396:neamine; C046366:angiogenin; D012259:Ribonuclease, Pancreatic
keywords: angiogenesis; angiogenin; cell proliferation; neamine; pancreatic cancer
references.citation: Oncogene. 2005 Jan 13;24(3):445-56
references.pmid: 15558023
references.citation: Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):442-6
references.pmid: 7831307
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):1981-8
references.pmid: 19276260
references.citation: Eur J Cancer. 1997 Jan;33 Suppl 1:S18-22
references.pmid: 9166095
references.citation: Cancer Res. 2005 Feb 15;65(4):1352-60
references.pmid: 15735021
references.citation: Cancer. 2000 May 15;88(10):2239-45
references.pmid: 10820344
references.citation: Oncol Lett. 2015 Jul;10(1):137-142
references.pmid: 26170989
references.citation: Antimicrob Agents Chemother. 1987 Apr;31(4):570-4
references.pmid: 3606061
references.citation: Lancet. 2011 Aug 13;378(9791):607-20
references.pmid: 21620466
references.citation: Biochem Biophys Res Commun. 1997 Sep 18;238(2):305-12
references.pmid: 9299500
references.citation: World J Gastroenterol. 2014 Oct 7;20(37):13343-68
references.pmid: 25309069
references.citation: J Virol. 2011 Mar;85(6):2666-85
references.pmid: 21209106
references.citation: Cancer Res. 1994 Sep 1;54(17):4576-9
references.pmid: 8062244
references.citation: J Virol. 2013 Nov;87(21):11806-20
references.pmid: 23986578
references.citation: Saudi Med J. 2010 Dec;31(12):1309-14
references.pmid: 21135992
references.citation: J Virol. 2009 Apr;83(7):3342-64
references.pmid: 19158252
references.citation: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8745-52
references.pmid: 16361562
references.citation: Lung Cancer. 2009 Oct;66(1):28-36
references.pmid: 19423182
references.citation: Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9791-5
references.pmid: 9707554
references.citation: JOP. 2006 Mar 09;7(2):163-73
references.pmid: 16525200
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):573-80
references.pmid: 23904380
references.citation: Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1677-81
references.pmid: 8127865
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: Cancer Chemother Pharmacol. 2015 Mar;75(3):465-74
references.pmid: 25552400
references.citation: Clin Cancer Res. 2001 Nov;7(11):3598-605
references.pmid: 11705882
references.citation: Biochemistry. 1985 Sep 24;24(20):5480-6
references.pmid: 4074709
references.citation: Anticancer Res. 2014 May;34(5):2113-21
references.pmid: 24778013
references.citation: Eur J Cancer. 1998 Aug;34(9):1439-47
references.pmid: 9849429
references.citation: Cancer Res. 1996 Jun 15;56(12):2703-6
references.pmid: 8665497